The Chinese pharmaceutical company, Chongqing Zhifei Biological Products, has launched a new vaccine called Zifivax to combat COVID-19. According to the resolution published by Invima —the institution in charge of national health references— there are sufficient reasons to approve of vaccine, as it has proven to be effective against COVID-19.
Like the other vaccines, the recombinant vaccine is also injectable and requires a three-dose schedule for full effectiveness, with each dose being administered within 4 weeks of each other. The clinical trial support, which is currently in phase III, is looking for 28,500 volunteers in order to demonstrate efficacy. Following studies in China, it was determined to be 81.76% effective in preventing COVID-19. Zifivax was also shown to be effective against the Omicron variant and new variants as they emerge.